A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies

Clinical Cancer Research

Volumn 16, Issue 4, 2010, Pages 1256-1263

  Camidge, D Ross ^a   Herbst, Roy S ^b   Gordon, Michael S ^c   Eckhardt, S Gail ^a   Kurzrock, Razelle ^b   Durbin, Blythe ^d   Ing, Josephine ^d   Tohnya, Tanyifor M ^d   Sager, Jason ^e   Ashkenazi, Avi ^d   Bray, Gordon ^d   Mendelson, David ^c  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c Premiere Oncology of Arizona   (United States)

^d GENENTECH INC   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DEATH RECEPTOR 5; IMMUNOGLOBULIN G1 ANTIBODY; PRO 95780; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BREAST CANCER; CHILL; CHONDROSARCOMA; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COLORECTAL CANCER; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GRANULOSA CELL TUMOR; HALF LIFE TIME; HEAD AND NECK CANCER; HEADACHE; HUMAN; IMMUNOGENICITY; KIDNEY CANCER; LUNG CANCER; LUNG EMBOLISM; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MELANOMA; MULTIPLE CYCLE TREATMENT; MULTIPLE DRUG DOSE; NONHODGKIN LYMPHOMA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; SAGITTAL SINUS THROMBOSIS; SIDE EFFECT; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 76749110412     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-1267     Document Type: Article

References (29)

1. Gerl R, Vaux DL. Apoptosis in the development and treatment of cancer. Carcinogenesis 2005;26:263-70.
2. Ashkenazi A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov 2008;7:1001-12.
3. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002;2:420-30.
4. Jin H, Yang R, Fong S, et al. Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Cancer Res 2004;64:4900-5.
5. Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 2005;55:178-94.
6. Hollstein M, Rice K, Greenblatt MS, et al. Database of p53 somatic mutations in human tumors and cell lines. Nucleic Acids Res 1994; 22:3551-5.
7. Lee JM, Bernstein A. Apoptosis, cancer and the p53 tumour suppressor gene. Cancer Metastasis Rev 1995;14:149-61.
8. Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2002;2:277-88.
9. Adams C, Totpal K, Lawrence D, et al. Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5. Cell Death Differ 2008;15:751-61.
10. Jin H, Yang R, Ross J, et al. Cooperation of the agonistic DR5 antibody apomab with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Clin Cancer Res 2008;14:7733-40.
11. Mouzakiti A, Packham G. Regulation of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Burkitt's lymphoma cell lines. Br J Haematol 2003;122:61-9.
12. Daniels RA, Turley H, Kimberley FC, et al. Expression of TRAIL and TRAIL receptors in normal and malignant tissues. Cell Res 2005;5: 430-8.
13. Koornstra JJ, Jalving M, Rijken FE, et al. Expression of tumour necrosis factor-related apoptosis-inducing ligand death receptors in sporadic and hereditary colorectal tumours: potential targets for apoptosis induction. Eur J Cancer 2005;41:1195-202.
14. Adams C, Totpal K, Deforge L, et al. Anti-tumor activity of Apomab: a fully human agonistic monoclonal antibody that targets the proapoptotic receptor DR5. American Association for Cancer Research Annual Meeting 2007;abstract LB-317.
15. Daniel D, Yang B, Totpal K, et al. Activity of Apomab, a fully human agonistic DR5 monoclonal antibody, in models of non Hodgkin's lymphoma. Annual AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2007;abstract 902.
16. National Cancer Institute: Definitions for CTCAE Version 3.0, 2003.
17. Therasse P, Arbuck SG, Eisenhauer EA, et al, European Organization for Research and Treatment of CancerNational Cancer Institute of the United StatesNational Cancer Institute of Canada. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
18. Srivastava RK. TRAIL/Apo-2L: mechanisms and clinical applications in cancer. Neoplasia 2001;3:535-46.
19. Jo M, Kim TH, Seol DW, et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 2000;6:564-7.
20. Saleh MN, Percent I, Wood TE, et al. A phase I study of CS-1008 (humanized monoclonal antibody targeting death receptor 5 or DR5), administered weekly to patients with advanced solid tumors or lymphomas. Proc Am Soc Clin Oncol 2008;abstract 3537.
21. Plummer R, Attard G, Pacey S, et al. Phase I and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin Cancer Res 2007;13:6187-94.
22. LoRusso P, Hong D, Heath E, et al. First-in-human study of AMG 655, a pro-apoptotic TRAIL receptor-2 agonist, in adult patients with advanced solid tumors. American Society of Clinical Oncology Annual Meeting 2007;abstract 3534.
23. Herbst RS, Mendelson DS, Ebbinghaus S, et al. A phase I safety and pharmacokinetic study of recombinant Apo2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer. Proc Am Soc Clin Oncol 2006;24:abstract 3013.
24. Ling J, Herbst RS, Mendelson DS, et al. Apo2L/TRAIL pharmacokinetics in a phase Ia trial in advanced cancer and lymphoma. Proc Am Soc Clin Oncol 2006;24:abstract 3047.
25. Hotte SJ, Hirte HW, Chen EX, et al. A Phase 1 study of Mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. Clin Cancer Res 2008;14:3450-5.
26. Sharma S, de Vries EG, Infante JR, et al. Phase I trial of LBY135, a monoclonal antibody against DR5, alone and in combination with capecitabine in advanced solid tumors. Proc Am Soc Clin Oncol 2008; abstract 3538.
27. Behbakht K, Qamar L, Aldridge CS, et al. Six1 overexpression in ovarian carcinoma causes resistance to TRAIL-mediated apoptosis and is associated with poor survival. Cancer Res 2007;67: 3036-42.
28. Camidge DR. Apomab: an agonist monoclonal antibody directed against Death Receptor 5/TRAIL-Receptor 2 for use in the treatment of solid tumors. Expert Opin Biol Ther 2008;8:1167-76.
29. Wagner K, Punnoose E, Januario T, et al. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med 2007;13:1070-7.